Last reviewed · How we verify
OnabotulinumtoxinA 100 UNT [Botox]
OnabotulinumtoxinA blocks the release of acetylcholine at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
OnabotulinumtoxinA blocks the release of acetylcholine at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Strabismus.
At a glance
| Generic name | OnabotulinumtoxinA 100 UNT [Botox] |
|---|---|
| Also known as | Botox, Onabot/A |
| Sponsor | Women and Infants Hospital of Rhode Island |
| Drug class | Neurotoxin; botulinum toxin type A |
| Target | SNAP-25 (synaptosome-associated protein of 25 kDa) |
| Modality | Small molecule |
| Therapeutic area | Neurology; Dermatology; Aesthetics |
| Phase | FDA-approved |
Mechanism of action
The drug is a botulinum toxin serotype A that irreversibly cleaves SNAP-25, a protein essential for acetylcholine vesicle release. This prevents neurotransmitter signaling at the neuromuscular junction, resulting in flaccid paralysis of targeted muscles. The effect is temporary, lasting 3–4 months, after which nerve terminals regenerate and muscle function returns.
Approved indications
- Cervical dystonia
- Blepharospasm
- Strabismus
- Chronic migraine
- Severe primary axillary hyperhidrosis
- Glabellar lines (aesthetic)
- Crow's feet (aesthetic)
- Forehead lines (aesthetic)
Common side effects
- Headache
- Neck pain
- Injection site pain
- Muscle weakness
- Eyelid ptosis
- Diplopia
- Flu-like syndrome
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: